TTAB Deems PULSE DECOMPOSITION ANALYSIS Generic for . . . . Guess What?
The Board affirmed a refusal to register, on the Supplemental Register, the proposed mark PULSE DECOMPOSITION ANALYSIS, finding it to be generic for patient monitors and patient sensors for monitoring and measuring physiological parameters. Applicant CareTaker Medical argued that the proposed mark identifies a method or function by which the sensors and monitors measure blood pressure, not the device itself. The Board was unmoved. In re CareTaker Medical, LLC, Serial No. 90881906 (August 7, 2026) [not precedential] (Opinion by Judge Robert Lavache).
The Board stated the issue as this: "the ultimate inquiry here is whether healthcare and medical professionals understand PULSE DECOMPOSITION ANALYSIS to refer to a class or category of 'patient monitors and patient sensors,' or to a key aspect or subcategory of those goods."
Examining Attorney Candace W. Hays maintained that a key aspect or feature of CareTaker's goods is the measurement of blood pressure through a particular method of analyzing a patient’s pulse. In support, she pointed to various articles referring to Pulse Decomposition Analysis (PDA) as a "non-invasive method of measuring blood pressure without a cuff," and to CareTaker's own patent and its website discussing measurement of breathing rate by pulse decomposition analysis. the Board concluded that the phrase "refers to a method for analyzing a patient’s pulse waves to measure, inter alia, blood pressure and other vascular characteristics."
CareTaker argued that the proposed mark cannot be deemed generic because “[t]here is no evidence of record that shows ‘pulse decomposition analysis’ being used as the name of a patient sensor or medical device, and thus “[t]he record does not show that one could go to a medical supply store and ask to purchase a ‘pulse decomposition analysis’ or go to a hospital and ask that a ‘pulse decomposition analysis’ be brought into the room." The Board was not persuaded.
Nor was the Board persuaded by the argument that PULSE DECOMPOSITION ANALYSIS can't be generic because it refers only to “the method applied by Applicant” or “a function that can be applied to data collected by a sensor.”
The Board found that CareTaker's arguments rely "on an unduly narrow application of the genericness standard." "As the Examining Attorney points out, '[a]ny term that the relevant public understands to refer to a particular genus of goods and/or services is generic.' * * * [T]hat would include a term that identifies a key aspect or subcategory of the relevant genus."
Finally, the Board shrugged off CareTaker's assertion that PULSE DECOMPOSITION ANALYSIS can't be generic because it is used only by Applicant, or only in connection with Applicant’s goods. "[W]hile evidence that a term is used by competitors, if it exists, may be relevant to a genericness analysis, it is not required where, as here, other evidence shows that consumers will understand the term to refer to the genus."
And so, the Board affirmed the refusal under Sections 23(c) and 45 of the Trademark Act.
Read comments and post your comment here.
TTABlogger comment: I think this is one of those "key aspect" cases that goes too far. Remember BLUEBERRY MUFFIN for beer?
Text Copyright John L. Welch 2026.















